Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04505904 · ClinicalTrials.gov registry record · NA

Oxytocin and Approach-avoid in Grief

A NA study, sponsored by University of Arizona.

Completed
Registry status
NA
Development phase
44
Enrollment target

NCT04505904 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 44 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04505904, a NA study, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target

Study Summary

This is a completed project which was initiated prior to January 18,2017 Background: Theoretical models of complicated grief (CG) suggest that maladaptive approach (e.g., perseverative proximity-seeking of the deceased) or avoidance (e.g., excessive avoidance of reminders) behaviors interfere with a person's ability to integrate the loss and recover from their loved one's death. Due in part to conflicting evidence, little mechanistic understanding of how these behaviors develop in grief exists. We sought to (1) identify behavioral differences between CG and non-CG groups based on implicit bias for grief-, deceased-, and social-related stimuli, and (2) test the role of the neuropeptide oxytocin in shaping approach/avoidance bias. Methods: Widowed older adults with and without CG completed an approach/avoidance task measuring implicit bias for personalized, non-specific, grief-related, and other stimuli. In a double-blinded, randomized, counterbalanced design, each participant attended both an intranasal oxytocin session and a placebo session. Aims were to (1) identify differential effects of CG and stimulus type on implicit approach/avoidance bias \[placebo session\], and (2) investigate interactive effects of CG, stimulus type, and oxytocin vs. placebo on approach/avoidance bias \[both sessions\].

Interventions

  • DRUG Placebo
  • DRUG Syntocinon

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2015-03-20
Est. Completion 2017-05-12
Phase NA

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT04505904

The ClinicalTrials.gov registry entry for NCT04505904 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04505904 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04505904 about?

NCT04505904 is a clinical study titled "Oxytocin and Approach-avoid in Grief". This is a completed project which was initiated prior to January 18,2017 Background: Theoretical models of complicated grief (CG) suggest that maladaptive approach (e.g., perseverative proximity-seeking of the deceased) or avoidance (e.g., excessive avoidance of reminders) behaviors interfere with ...

What is the current status of trial NCT04505904?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2015-03-20. Estimated completion is 2017-05-12.

What interventions are being tested in trial NCT04505904?

The interventions under investigation include: Placebo (DRUG), Syntocinon (DRUG).

Who is sponsoring clinical trial NCT04505904?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.